Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558296 · ClinicalTrials.gov registry record · Phase 3
Bexagliflozin Efficacy and Safety Trial
A Phase 3 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,700
- Enrollment target
NCT02558296: Completed Phase 3 study, sponsored by Theracos.
NCT02558296 is a Phase 3 study that has completed, run by Theracos. The registered enrollment target is 1,700 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (120% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02558296, a Phase 3 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,700 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events. The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.
Primary Outcome
The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with increased risk of cardiovascular adverse events.
Interventions
- DRUG Placebo
- DRUG Bexagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,700 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-10-23 |
| Phase | Phase 3 |
What the finished NCT02558296 record still lists
NCT02558296 is an interventional study that assigns participants to a tested intervention. Its 1,700 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (120% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02558296 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02558296 about?
NCT02558296 is a clinical study titled "Bexagliflozin Efficacy and Safety Trial". The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events. The data from this study will be combined with the data from other bexagliflozin st...
What is the current status of trial NCT02558296?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,700 participants. The study started on 2015-10. Estimated completion is 2019-10-23.
What interventions are being tested in trial NCT02558296?
The interventions under investigation include: Placebo (DRUG), Bexagliflozin (DRUG).
Who is sponsoring clinical trial NCT02558296?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02558296's enrollment target sits among peer trials
1,700 132nd of 2000 higher than 1,867 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia